LIVIVO - Search results -

Search results

Result 1 - 10 of total 29

Search options

Article ; Online: Outbreak of carbapenemase-producing

Regad, Marie / Lizon, Julie / Alauzet, Corentine / Roth-Guepin, Gabrielle / Bonmati, Caroline / Pagliuca, Simona / Lozniewski, Alain / Florentin, Arnaud

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

2024 Volume 29, Issue 14

Abstract: In 2019-2022, a prolonged outbreak of oxacillinase (OXA)-48- ... ...

Abstract	In 2019-2022, a prolonged outbreak of oxacillinase (OXA)-48-producing
MeSH term(s)	Humans ; Wastewater ; Cross Infection/microbiology ; beta-Lactamases ; Bacterial Proteins/genetics ; Disease Outbreaks ; Hospitals ; Critical Care ; Klebsiella pneumoniae ; Citrobacter
Chemical Substances	carbapenemase (EC 3.5.2.6) ; Wastewater ; beta-Lactamases (EC 3.5.2.6) ; Bacterial Proteins
Language	English
Publishing date	2024-04-04
Publishing country	Sweden
Document type	Journal Article
ZDB-ID	1338803-4
ISSN	1560-7917 ; 1025-496X
ISSN (online)	1560-7917
ISSN	1025-496X
DOI	10.2807/1560-7917.ES.2024.29.14.2300386
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5066: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML.

Gyan, Emmanuel / Pigneux, Arnaud / Hunault, Mathilde / Peterlin, Pierre / Carré, Martin / Bay, Jacques-Olivier / Bonmati, Caroline / Gallego-Hernanz, Maria-Pilar / Lioure, Bruno / Bertrand, Philippe / Vallet, Nicolas / Ternant, David / Darrouzain, François / Picou, Frédéric / Béné, Marie-Christine / Récher, Christian / Hérault, Olivier

Scientific reports

2022 Volume 12, Issue 1, Page(s) 9748

Abstract: The treatment of acute myeloid leukemia (AML) with unfavorable cytogenetics treatment remains a challenge. We previously established that ex vivo exposure of AML blasts to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or fish oil emulsion (FO) ...

Abstract	The treatment of acute myeloid leukemia (AML) with unfavorable cytogenetics treatment remains a challenge. We previously established that ex vivo exposure of AML blasts to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or fish oil emulsion (FO) induces Nrf2 pathway activation, metabolic switch, and cell death. The FILO group launched a pilot clinical study to evaluate the feasibility, safety, and efficacy of the adjunction of a commercial FO emulsion to 3 + 7 in untreated AML with unfavorable cytogenetics. The primary objective was complete response (CR). Thirty patients were included. FO administration raised the plasma levels of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids (p < 0.001). The pharmacokinetics of cytarabine and daunorubicin were unaffected. A historical comparison to the LAM2001 trial (Lioure et al. Blood 2012) found a higher frequency of grade 3 serious adverse events, with no drug-related unexpected toxicity. The CR rate was 77%, and the partial response (PR) 10%, not significantly superior to that of the previous study (CR 72%, PR 1%). RT-qPCR analysis of Nrf2 target genes and antioxidant enzymes did not show a significant in vivo response. Overall, FO emulsion adjunction to 3 + 7 is feasible. An improvement in CR was not shown in this cohort of high-risk patients. The present data does not support the use of FO in adjunction with 3 + 7 in high-risk AML patients.ClinicalTrials.gov identifier: NCT01999413.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/therapeutic use ; Daunorubicin/therapeutic use ; Docosahexaenoic Acids/therapeutic use ; Eicosapentaenoic Acid ; Emulsions/therapeutic use ; Feasibility Studies ; Fish Oils/therapeutic use ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/genetics ; NF-E2-Related Factor 2/genetics
Chemical Substances	Emulsions ; Fish Oils ; NF-E2-Related Factor 2 ; Cytarabine (04079A1RDZ) ; Docosahexaenoic Acids (25167-62-8) ; Eicosapentaenoic Acid (AAN7QOV9EA) ; Daunorubicin (ZS7284E0ZP)
Language	English
Publishing date	2022-06-13
Publishing country	England
Document type	Clinical Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-022-13626-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Images in clinical medicine. Acquired melanonychia.

Ranta, Dana / Bonmati, Caroline

The New England journal of medicine

2009 Volume 361, Issue 12, Page(s) 1188

MeSH term(s)	Aged, 80 and over ; Diagnosis, Differential ; Female ; Humans ; Hydroxyurea/adverse effects ; Nail Diseases/chemically induced ; Nail Diseases/pathology ; Pigmentation Disorders/chemically induced ; Pigmentation Disorders/pathology ; Thrombocythemia, Essential/drug therapy
Chemical Substances	Hydroxyurea (X6Q56QN5QC)
Language	English
Publishing date	2009-09-17
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMicm0804222
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France.

Dumas, Pierre-Yves / Bertoli, Sarah / Bonmati, Caroline / Carre, Martin / Lambert, Juliette / Ojeda-Uribe, Mario / Chantepie, Sylvain / Paul, Franciane / Jourdan, Eric / Haiat, Stéphanie / Tavernier, Emmanuelle / Peterlin, Pierre / Marolleau, Jean-Pierre / Laribi, Kamel / Orvain, Corentin / Cabrera, Quentin / Turlure, Pascal / Girault, Stéphane / Balsat, Marie /

Bernard, Marc / Bene, Marie-Christine / Pigneux, Arnaud / Dombret, Hervé / Récher, Christian

Leukemia research

2022 Volume 120, Page(s) 106901

MeSH term(s)	Acute Disease ; Adult ; COVID-19/epidemiology ; France/epidemiology ; Humans ; Leukemia, Myeloid, Acute ; SARS-CoV-2
Language	English
Publishing date	2022-06-20
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	752396-8
ISSN	1873-5835 ; 0145-2126
ISSN (online)	1873-5835
ISSN	0145-2126
DOI	10.1016/j.leukres.2022.106901
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1321: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study.

Orvain, Corentin / Chantepie, Sylvain / Thomas, Xavier / Escofrre-Barbe, Martine / Huguet, Francoise / Desbrosses, Yohan / Guillerm, Gaelle / Uzunov, Madalina / Leguay, Thibaut / Barbieux, Sarah / Vey, Norbert / Chevallier, Patrice / Malfuson, Jean-Valere / Lepretre, Stephane / Baumann, Michael / Aykut, Murat / Chaib, Abdelaziz / Joris, Magalie / Zerazhi, Hacene /

Stussi, Georg / Chapiro, Jacques / Berthon, Celine / Bonmati, Caroline / Jourdan, Eric / Carp, Diana / Marcais, Amb Roise / Gallego-Hernanz, Maria-Pilar / Vaida, Iona / Bilger, Karin / Villate, Alban / Pasquier, Florence / Chalandon, Yves / Maury, Sebastien / Lheritier, Veronique / Ifrah, Norbert / Dombret, Herve / Boissel, Nicolas / Hunault-Berger, Mathilde

Haematologica

2023 Volume 108, Issue 12, Page(s) 3287–3297

Abstract: Whereas the prognosis of adult patients with Philadelphia-negative acute lymphoblastic leukemia (ALL) has greatly improved since the advent of pediatric-inspired regimens, the impact of initial central nervous system (CNS) involvement has not been ... ...

Abstract	Whereas the prognosis of adult patients with Philadelphia-negative acute lymphoblastic leukemia (ALL) has greatly improved since the advent of pediatric-inspired regimens, the impact of initial central nervous system (CNS) involvement has not been formerly re-evaluated. We report here the outcome of patients with initial CNS involvement included in the pediatric-inspired prospective randomized GRAALL-2005 study. Between 2006 and 2014, 784 adult patients (aged 18-59 years) with newly diagnosed Philadelphia-negative ALL were included, of whom 55 (7%) had CNS involvement. In CNSpositive patients, overall survival was shorter (median 1.9 years vs. not reached, HR=1.8 [1.3-2.6], P<0.001). While there was no statistical difference in cumulative incidence of relapse between CNS+ and CNS- patients (HR=1.5 [0.9-2.5], P=0.11), non-relapse mortality was significantly higher in those with initial CNS disease (HR=2.1 [1.2-3.5], P=0.01). This increase in toxicity was mostly observed in patients randomized to the high-dose cyclophosphamide arm and in those who received allogeneic stem cell transplantation. Exploratory landmark analyses did not show any association between either cranial irradiation or allogeneic stem cell transplantation and outcome. Despite improved outcome in young adult ALL patients with pediatric-inspired protocols, CNS involvement is associated with a worse outcome mainly due to excess toxicity, without improved outcome with allogeneic SCT.
MeSH term(s)	Young Adult ; Humans ; Prospective Studies ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications ; Cyclophosphamide ; Hematopoietic Stem Cell Transplantation ; Central Nervous System ; Treatment Outcome
Chemical Substances	Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2023-12-01
Publishing country	Italy
Document type	Randomized Controlled Trial ; Journal Article
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2022.282332
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study.

Orvain, Corentin / Balsat, Marie / Tavernier, Emmanuelle / Marolleau, Jean-Pierre / Pabst, Thomas / Chevallier, Patrice / de Gunzburg, Noémie / Cacheux, Victoria / Huguet, Françoise / Chantepie, Sylvain / Caillot, Denis / Chalandon, Yves / Frayfer, Jamilé / Bonmati, Caroline / Lheritier, Véronique / Ifrah, Norbert / Dombret, Hervé / Boissel, Nicolas / Hunault-Berger, Mathilde

Blood

2020 Volume 136, Issue 3, Page(s) 328–338

Abstract: Patients undergoing treatment of acute lymphoblastic leukemia (ALL) are at risk for thrombosis, caused in part by the use of l-asparaginase (L-ASP). Antithrombin (AT) replacement has been suggested to prevent venous thromboembolism (VTE) and thus may ... ...

Abstract	Patients undergoing treatment of acute lymphoblastic leukemia (ALL) are at risk for thrombosis, caused in part by the use of l-asparaginase (L-ASP). Antithrombin (AT) replacement has been suggested to prevent venous thromboembolism (VTE) and thus may increase exposure to ASP. We report herein the results of the prophylactic replacement strategy in the pediatrics-inspired prospective GRAALL-2005 study. Between 2006 and 2014, 784 adult patients with newly diagnosed Philadelphia- ALL were included. The incidence rate of VTE was 16%, with 69% of cases occurring during induction therapy. Most patients received AT supplementation (87%). After excluding patients who did not receive L-ASP or who developed thrombosis before L-ASP, AT supplementation did not have a significant impact on VTE. Administration of fibrinogen concentrates was associated with an increased risk of VTE, whereas transfusion of fresh frozen plasma had no effect. Heparin prophylaxis was associated with an increased risk of VTE. Prophylactic measures were not associated with an increased risk of grade 3 to 4 bleeding complications. The rate of VTE recurrence after L-ASP reintroduction was 3% (1 of 34). In ALL patients receiving L-ASP therapy, the use of fibrinogen concentrates may increase the risk of thrombosis and should be restricted to rare patients with hypofibrinogenemia-induced hemorrhage. VTE developed despite extensive AT supplementation, which suggests the need for additional prophylactic measures. Although this large descriptive study was not powered to demonstrate the efficacy of these prophylactic measures, it provides important insight to guide future trial design. This trial was registered at www.clinicaltrials.gov as #NCT00327678.
MeSH term(s)	Adult ; Asparaginase/administration & dosage ; Asparaginase/adverse effects ; Female ; Fibrinogen/administration & dosage ; Follow-Up Studies ; Heparin/administration & dosage ; Humans ; Incidence ; Induction Chemotherapy/adverse effects ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology ; Venous Thromboembolism/blood ; Venous Thromboembolism/chemically induced ; Venous Thromboembolism/epidemiology ; Venous Thromboembolism/prevention & control
Chemical Substances	Fibrinogen (9001-32-5) ; Heparin (9005-49-6) ; Asparaginase (EC 3.5.1.1)
Language	English
Publishing date	2020-04-22
Publishing country	United States
Document type	Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2020004919
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.

Chiche, Edmond / Rahmé, Ramy / Bertoli, Sarah / Dumas, Pierre-Yves / Micol, Jean-Baptiste / Hicheri, Yosr / Pasquier, Florence / Peterlin, Pierre / Chevallier, Patrice / Thomas, Xavier / Loschi, Michael / Genthon, Alexis / Legrand, Ollivier / Mohty, Mohamad / Raffoux, Emmanuel / Auberger, Patrick / Caulier, Alexis / Joris, Magalie / Bonmati, Caroline /

Roth-Guepin, Gabrielle / Lejeune, Caroline / Pigneux, Arnaud / Vey, Norbert / Recher, Christian / Ades, Lionel / Cluzeau, Thomas

Blood advances

2021 Volume 5, Issue 1, Page(s) 176–184

Abstract: CPX-351 is a liposomal formulation of cytarabine and daunorubicin approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). We retrospectively analyzed ... ...

Abstract	CPX-351 is a liposomal formulation of cytarabine and daunorubicin approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). We retrospectively analyzed the efficacy and safety of CPX-351 in a real-world setting in 103 patients from 12 French centers, including the evaluation of molecular abnormalities at baseline and minimal residual disease (MRD) in responding patients, compared with a historical data set from Bordeaux-Toulouse DATAML registry. A favorable safety profile was observed, with a low frequency of alopecia (11%) and gastrointestinal toxicity (50%). The overall response rate after induction was 59%, and MRD <10-3 was achieved in 57% of complete response (CR)/CR with incomplete hematological recovery (CRi) patients. Only the presence of mutated TP53 (P = .02) or PTPN11 (P = .004) predicted lower response in multivariate analysis. Interestingly, high-risk molecular prognosis subgroups defined by 2017 European LeukemiaNet risk stratification, including ASXL1 and RUNX1 mutations, were not associated with a significantly lower response rate using CPX-351. With a median follow-up of 8.6 months, median overall survival (OS) was 16.1 months. Thirty-six patients underwent allogeneic stem cell transplantation with a significantly longer median OS compared with nontransplanted patients (P < .001). In multivariate analyses, only spliceosome mutations were associated with better OS (P = .04). In comparison with intensive chemotherapy, there was no difference in OS for patients <60 years. These data confirm the efficacy and safety of CPX-351 in high-risk AML (t-AML and MRC-AML) in a real-life setting. CPX-351 is a treatment of choice for patients aged ≥60 years.
MeSH term(s)	Adult ; Aged ; Cytarabine ; Daunorubicin ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Retrospective Studies
Chemical Substances	CPX-351 ; Cytarabine (04079A1RDZ) ; Daunorubicin (ZS7284E0ZP)
Language	English
Publishing date	2021-02-11
Publishing country	United States
Document type	Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2020003159
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status.

European journal of haematology

2021 Volume 106, Issue 6, Page(s) 859–867

Abstract: Objectives: The impact of conventional treatment for acute myeloid leukemia (AML) on the nutritional, cognitive, and functional status of elderly patients is seldom studied. This assessment was performed in the context of the LAMSA 2007 trial.: ... ...

Abstract	Objectives: The impact of conventional treatment for acute myeloid leukemia (AML) on the nutritional, cognitive, and functional status of elderly patients is seldom studied. This assessment was performed in the context of the LAMSA 2007 trial. Methods: The trial enrolled 424 patients with de novo AML. Among them, 316 benefited from geriatric assessment (GA) including nutritional, cognitive, and functional status and were scored according to Eastern Cooperative Oncology Group (ECOG) and sorror for the prediction of treatment toxicity, morbidity, and mortality. Patients were investigated at diagnosis for three times during follow-up. Results: This study showed that AML and its treatment have no impact on cognitive (P = .554) nor functional status (P = .842 for Activity of Daily Living and P = .087 for Instrumental Activities of Daily Living). The nutritional status improved over time (P = .041). None of these three parameters at baseline, associated or not with ECOG and sorror scores, impacted survivals or toxicities. Conclusions: The cognitive, functional, and nutritional status had no impact in this cohort of fit elderly AML patients without unfavorable cytogenetics. The GA tools used provided no additional information compared with ECOG and sorror scores, to predict toxicity, morbidity, or mortality due to intensive chemotherapy.
MeSH term(s)	Activities of Daily Living ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Cognition/drug effects ; Female ; Follow-Up Studies ; Geriatric Assessment ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Male ; Middle Aged ; Nutritional Status/drug effects ; Prospective Studies
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2021-03-27
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	392482-8
ISSN	1600-0609 ; 0902-4441
ISSN (online)	1600-0609
ISSN	0902-4441
DOI	10.1111/ejh.13624
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 323: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?

Filliatre-Clement, Lauriane / Broseus, Julien / Muller, Marc / Hosseini, Kossar / Rotonda, Christine / Schirmer, Luciane / Roth-Guepin, Gabrielle / Bonmati, Caroline / Feugier, Pierre / Béné, Marie-Christine / Perrot, Aurore

Hematological oncology

2018 Volume 37, Issue 1, Page(s) 80–84

Abstract: Obesity has been associated with an increased risk of developing acute myeloblastic leukaemia (AML). The outcome of AML patients could thus be dependent on their nutritional status that can be evaluated by the simple measurement of serum albumin (SA) and ...

Abstract	Obesity has been associated with an increased risk of developing acute myeloblastic leukaemia (AML). The outcome of AML patients could thus be dependent on their nutritional status that can be evaluated by the simple measurement of serum albumin (SA) and body mass index (BMI). These two parameters could have a value as prognostic factors to guide patients' management. We evaluated the association between SA levels, BMI, and survival, evaluated as overall survival (OS) and event-free survival. Furthermore, we investigated the association between BMI, SA, and other prognostic factors of interest in AML. This retrospective single-center study included 159 patients diagnosed with AML at Nancy Hospital between 2005 and 2013, treated with aracytine and anthracycline. Forty-four percent of patients presented with normal weight while 56% were obese/overweight. Serum albumin levels were <30 g/L for 49 patients, and ≥30 g/L for 110. Thirty-four patients with low SA levels were also obese. Favourable OS was associated with SA levels ≥30 g/L (HR = 0.467; 95% CI 0.230-0.946; P = .034) but was not impacted by the BMI. Serum albumin levels appear to be an independent prognostic factor in AML and a better parameter than BMI for evaluating the nutritional status of patients at diagnosis.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Body Mass Index ; Female ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/blood ; Leukemia, Myeloid, Acute/epidemiology ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Nutritional Status ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Serum Albumin ; Survival Analysis
Chemical Substances	Biomarkers ; Serum Albumin
Language	English
Publishing date	2018-10-05
Publishing country	England
Document type	Journal Article
ZDB-ID	604884-5
ISSN	1099-1069 ; 0278-0232
ISSN (online)	1099-1069
ISSN	0278-0232
DOI	10.1002/hon.2543
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1816: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.

Michallet, Mauricette / Sobh, Mohamad / Morisset, Stephane / Deloire, Alexandre / Raffoux, Emmanuel / de Botton, Stephane / Caillot, Denis / Chantepie, Sylvain / Girault, Stephane / Berthon, Celine / Bertoli, Sarah / Lepretre, Stephane / Leguay, Thibaut / Castaigne, Sylvie / Marolleau, Jean-Pierre / Pautas, Cecile / Malfuson, Jean-Valere / Veyn, Norbert / Braun, Thorsten /

Gastaud, Lauris / Suarez, Felipe / Schmidt, Aline / Gressin, Remy / Bonmati, Caroline / Celli-Lebras, Karine / El-Hamri, Mohamed / Ribaud, Patricia / Dombret, Herve / Thomas, Xavier / Bergeron, Anne

Clinical lymphoma, myeloma & leukemia

2021 Volume 22, Issue 5, Page(s) 311–318

Abstract: Background: Although recommended in patients with acute myeloblastic leukaemia (AML) after induction chemotherapy, real-life use of antifungal prophylaxis (AFP) is different among centres.: Materials and methods: This is an ancillary study to a ... ...

Abstract	Background: Although recommended in patients with acute myeloblastic leukaemia (AML) after induction chemotherapy, real-life use of antifungal prophylaxis (AFP) is different among centres. Materials and methods: This is an ancillary study to a randomized trial on intensive induction chemotherapy in AML patients (ALFA-0702/NCT00932412), where AFP with posaconazole was recommended. IFIs were graded by investigators and by central reviewers according to the revised EORTC definitions. Experts conclusions were compared to the investigators' ones. Results: A total of 677 patients were included. Four AFP strategies were reported: Group-1: no AFP (n = 203, 30%), Group-2: posaconazole (n = 241, 36%), Group-3: posaconazole with other AFP (n = 142, 21%), Group-4: other AFP (n = 91, 13%). Experts graded more IFI than investigators: proven/probable IFI, 9.0% (n = 61) versus 6.2% (n = 42). The cumulative incidence at day60 of probable/proven IFI was 13.9% (Group-1); 7.9% (Group-2); 5.6% (Group-3); and 6.6% (Group-4). IFI onset was 26 (19-31) days after induction in Groups 2-3, versus 16 (9-25) days in Group 1 and 20 (12-24) days in Group 4 (P< .001). After a median follow-up of 27.5 months (0.4-73.4), the mortality rate was 38.3%, with 5.4% attributed to IFI. In multivariate analysis, IFI occurrence was an independent risk of death (HR5.63, 95%-CI 2.62-12.08, P< .001). EORTC recommendations were applied in only 57% of patients. In patients without IFI, the rate of AML complete remission was higher. Conclusions: In AML patients, AFP delayed the onset of IFI in addition of decreasing their rate. The frequent misidentification of IFI impacts their appropriate management according to recommendations. hematological remission was more frequent in patients without IFI.
MeSH term(s)	Acute Disease ; Antifungal Agents/therapeutic use ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/complications ; Leukemia, Myeloid, Acute/drug therapy ; Mycoses/etiology ; Mycoses/prevention & control ; alpha-Fetoproteins/therapeutic use
Chemical Substances	Antifungal Agents ; alpha-Fetoproteins
Language	English
Publishing date	2021-10-25
Publishing country	United States
Document type	Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2540992-X
ISSN	2152-2669 ; 2152-2650
ISSN (online)	2152-2669
ISSN	2152-2650
DOI	10.1016/j.clml.2021.10.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5903: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito